T. Rowe Price Investment Management, Inc. Blueprint Medicines Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 791,718 shares of BPMC stock, worth $71.9 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
791,718
Previous 1,003,196
21.08%
Holding current value
$71.9 Million
Previous $95.2 Million
10.33%
% of portfolio
0.05%
Previous 0.06%
Shares
8 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$603 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$593 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$533 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$294 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$223 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.42B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...